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a b s t r a c t
The prostate gland plays an important role in male reproduction, and is also an organ prone to diseases
such as benign prostatic hyperplasia (BPH) and prostate cancer. The prostate consists of ducts with an
inner layer of epithelium surrounded by stroma. Reciprocal signaling between these two cell compart-
ments is instrumental to normal prostatic development, homeostasis, regeneration, as well as tumor
formation. Hedgehog (HH) signaling is a master regulator in numerous developmental processes. In
many organs, HH plays a key role in epithelial–mesenchymal signaling that regulates organ growth and
tissue differentiation, and abnormal HH signaling has been implicated in the progression of various
epithelial carcinomas. In this review, we focus on recent studies exploring the multipotency of
endogenous postnatal and adult epithelial and stromal stem cells and studies addressing the role of
HH in prostate development and cancer. We discuss the implications of the results for a new
understanding of prostate development and disease. Insight into the cellular and molecular mechanisms
underlying epithelial–mesenchymal growth regulation should provide a basis for devising innovative
therapies to combat diseases of the prostate.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Hedgehog (HH) signaling plays an important role in develop-
ment, homeostasis, and cancer. In the prostate, HH signaling
modulates ductal morphogenesis through complex epithelial–
mesenchymal interactions during development. In the adult pros-
tate, HH is active in the stroma and HH-responding cells show
properties of stromal stem cells. In prostate cancer, HH mainly
signals through a paracrine mode, although uncertainty exists as
to whether autocrine HH signaling occurs in some tumor cells. The
potential roles of HH signaling in prostate development and cancer
have been previously summarized by the Bushman group and
others (Shaw and Bushman, 2007; Vezina and Bushman, 2007;
Gonnissen et al., 2013). Here we review new ﬁndings on the
multipotency of endogenous postnatal and adult epithelial and
stromal stem cells, stage-dependent roles of HH signaling in
prostate development, and the possible role of HH signaling in
prostate cancer, including its potential involvement in castration-
resistant prostate cancer.
Epithelial differentiation in prostate development
The prostate develops from the endodermal urogenital sinus
(UGS) and the surrounding urogenital sinus mesenchyme (UGM).
Prostate development is initiated by androgen acting on the
mesenchyme to induce reciprocal paracrine mesenchyme–epithe-
lial interactions (Cunha and Lung, 1978; Cunha et al., 1986). In
mouse, the prostatic ducts start to form after embryonic day 17
(E17) as solid epithelial buds formed from the UGE that invade the
surrounding UGM. Extensive epithelial branching occurs after
birth as nascent prostatic ducts elongate, branch, and arborize to
form elaborate networks; simultaneously, the buds canalize in a
proximal to distal direction along the developing ducts (Sugimura
et al., 1986a). Importantly, speciﬁcation of the prostate epithelium
requires androgen signaling in the mesenchyme, whereas andro-
gen signaling in the epithelium is responsible for differentiation of
the epithelium to enable production of prostatic secretions (Cunha
and Lung, 1978; Cunha et al., 1987).
The prostate is a heterogeneous gland with regionally distinct
features. The human prostate can be divided anatomically into
central, transition, and peripheral zones (Fig. 1). Interestingly,
carcinoma arises mainly in the peripheral zone, whereas benign
prostatic hyperplasia develops mainly in the transition zone
(McNeal, 1988; De Marzo et al., 1998). Unlike the human prostate
that is a compact gland, the mouse prostate includes four paired
lobes situated circumferentially around the urethra: anterior (AP),
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dorsal (DP), lateral (LP), and ventral (VP) prostate (Fig. 1). The DP
and LP are sometimes collectively referred to as the dorsolateral
lobes of the prostate (DLP). At birth, each lobe of the VP consists of
1–3 main ducts with secondary and tertiary branches, whereas the
more complex DLP initially has 9–12 unbranched proximal main
ducts on each side (Sugimura et al., 1986a). Ductal branching is
completed by 60–90 days after birth in mice with more than 70%
of the ducts being formed during the ﬁrst 15 days (Sugimura et al.,
1986a). Although the proximal part of the LP is adjacent to the DP,
the distal part of the LP grows closer to the VP, which may explain
the similarity of distal ductal architecture between LP and VP if the
environment is a critical determinant (Sugimura et al., 1986a).
Interestingly, chemically induced carcinoma occurs mainly in the
DLP (Bosland and Prinsen, 1990; Hoover et al., 1990; Shirai et al.,
1991), raising the possibility of similarities between the DLP in
mouse and peripheral zone in human; however, strong evolu-
tionary evidence is lacking to support this association.
The prostate epithelium differentiates in a proximal-to-distal wave
(Hayward et al., 1996a; Wang et al., 2001). In the pseudostratiﬁed
epithelium of the early UGS, most epithelial cells co-express p63 and
CK8 (Fig. 2), which later become markers for basal and luminal cells
respectively in the adult prostate (Wang et al., 2001; Pignon et al.,
2013). During prostatic ductal morphogenesis, two distinct types of
epithelial structures exist in the developing ducts: solid cords and
canalized ducts (Hayward et al., 1996a; Wang et al., 2001). In distal
solid epithelial cords, the differentiation marker proﬁle is similar to
that seen in embryonic UGE; all cells co-express p63 and CK8 (Fig. 2),
with a few cells expressing CK5, another marker for basal cells in the
adult prostate (Wang et al., 2001; Pignon et al., 2013). In proximal
canalized ducts, epithelial cells separate into CK8þ luminal cells and
p63þ basal cells (Wang et al., 2001; Ousset et al., 2012; Pignon et al.,
2013). In the adult mouse prostate, the epithelium consists of tall
columnar luminal cells, a discontinuous layer of basal cells (a
continuous layer in human), and rare neuroendocrine cells. The
expression of luminal and basal markers is largely mutually exclusive,
although a small population of basal cells has been reported in the
human prostate to co-express luminal and basal markers (Bonkhoff et
al., 1994; Robinson et al., 1998; Wang et al., 2001). A similar wave of
differentiation has been observed during development of the human
prostate: initially both luminal and basal markers are co-expressed in
the growing epithelial buds, and gradually segregate into separate
compartments (Letellier et al., 2007; Trompetter et al., 2008).
To elucidate the lineage hierarchy of epithelial cell types during
embryonic prostate development, Pignon et al. (2013) generated
knock-in mice expressing Cre recombinase under the control of
the p63 promoter and crossed these mice to R26YFP reporter mice.
Using p63Cre/þ; R26YFP/þ mice to fate map p63þ cells, they found
that YFPþ cells contributed to all three epithelial lineages of the
adult prostate, indicating p63þ cells are multipotent during the
embryonic stage. To study the fate of basal epithelial cells during
postnatal development, Ousset et al. (2012) used basal cell speciﬁc
K5CreER/þ ; R26YFP/þ mice and treated them with tamoxifen at P1 to
label CK5þ basal cells. After 4 weeks of chase, they identiﬁed
YFPþ basal, luminal, and neuroendocrine cells, indicating that
CK5þ cells at P1 are multipotent. To verify the result, they used a
different mouse line to label basal cells (CK14-rtTA; TetO-Cre;
R26YFP) and found that K14þ basal cells also exhibit multipotency
at P1. Furthermore, by titrating down doxycycline to allow clonal
analysis, they found that while some YFPþ clones contained both
basal and luminal cells, other clones contained only basal cells or
luminal cells, demonstrating that at P1 some CK14þ cells are
already committed to being unipotent basal or luminal progeni-
tors. Interestingly, in 6-week-old mice intermediate cells which
expressed both CK5 and CK8 were only found in clones containing
both basal and luminal cells 4 weeks after doxycycline adminis-
tration, suggesting intermediate cells likely represent a transi-
tional stage between multipotent cells and differentiated cells.
Using CK8CreER; R26YFP mice to label CK8þ luminal cells at P1,
analysis of YFPþ cells in 4-week-old mice revealed that YFPþ cells
only contributed to CK8þ luminal cells, indicating CK8þ luminal
cells at P1 are unipotent and can only generate luminal cells. In
summary, prostate epithelial cells are heterogeneous and become
lineage-restricted during development.
An important question regarding the ontogeny of the epithelial
cell lineage is whether basal cells are required for the formation of
luminal cells; in other words, whether multipotent epithelial cells
undergo a strict linear differentiation from basal cells to luminal
cells. The p53 homolog p63 is expressed in the basal cells of many
epithelial organs, including the prostate, and is required for the
development of numerous epithelia (Signoretti et al., 2000). p63
null mutant mice fail to develop a prostate, suggesting p63 plays a
critical role in prostate development (Signoretti et al., 2000).
Surprisingly, embryonic UGSs from p63 null mice transplanted
under the kidney capsule of adult immunodeﬁcient male mice are
able to differentiate into luminal cells and neuroendocrine cells
but not basal cells, indicating that p63 is essential for the
differentiation of basal cells, but p63 and thus basal cells are not
required for the differentiation of luminal and neuroendocrine
cells (Kurita et al., 2004). Luminal epithelial cells can therefore
form through bypassing normal basal cell differentiation. The
luminal cells generated from p63 null UGS, however, show a
prominent phenotype of goblet mucinous epithelial cells,
Fig. 1. Schematic diagrams of mouse and human prostate. (A) Mouse prostate consists of four pairs of lobes arranged circumferentially around the urethra. (B) Human
prostate is a compact gland, which can be divided into 3 zones: central, transition, and peripheral zones. AP, anterior prostate; DP, dorsal prostate, LP, lateral prostate; VP,
ventral prostate; SV, seminal vesicle; U, urethra.
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resembling the intestinal epithelium (Kurita et al., 2004); there-
fore, p63 and thus basal cells likely play an important role in the
proper differentiation of prostate-speciﬁc luminal cells. In addition
to p63, transcriptional factors such as Foxa1 were found to play an
important role during prostate epithelial differentiation (Gao
et al., 2005).
Mesenchymal differentiation in prostate development
There are reciprocal interactions between UGM and UGE during
prostate development. UGM speciﬁes prostatic epithelial identity
and induces epithelial budding, and likewise the developing
prostatic epithelium induces smooth muscle differentiation and
patterning of the UGM (Cunha et al., 1996; Hayward et al., 1998). In
transplantation experiments, when UGM alone is transplanted
under the kidney capsule of male nude mice, only a small amount
of smooth muscle differentiates in the grafts (Hayward et al.,
1996c). In contrast, tissue recombinants consisting of UGM and
UGE develop prostatic ducts with epithelial cells (basal and
luminal) surrounded by smooth muscle bundles (Hayward et al.,
1996c). Importantly, smooth muscle cells can be speciﬁed in the
UGM not only by UGE, but also by epithelium from adult prostate
or adult bladder, indicating common inductive signals across
epithelial types and stages (Cunha et al., 1992). SHH is likely to
be one of the inductive signals, as it has been postulated to play a
critical role during the development of smooth muscle in bladder
(Tasian et al., 2010) and gut (Mao et al., 2010).
Similar to the developmental sequence of the prostatic epithe-
lium, smooth muscle develops in a proximal to distal order
(Hayward et al., 1996b). One study of stromal development in
the rat VP showed that the ﬁrst mesenchymal marker to be
detected is vimentin, which is initially expressed throughout the
mesenchyme surrounding the UGE (Hayward et al., 1996b). Sub-
sequently, smooth muscle markers are expressed in an orderly
sequence from proximal to distal: ﬁrst α-SMA, followed by
vinculin, myosin, desmin, and laminin (Hayward et al., 1996b).
Signiﬁcantly, smooth muscle bundles are thicker in the proximal
portions of the ducts than in the distal portions in the adult
prostate, perhaps reﬂecting a longer time window for differentia-
tion. Vimentin expression becomes largely restricted to the inter-
ductal ﬁbroblasts during prostate development (Hayward et al.,
1996b).
In the adult mouse prostate, using molecular marker expres-
sion and cell location, we found that stromal cells can be further
classiﬁed into four subtypes: subepithelial cells, smooth muscle
cells, wrapping cells, and interstitial ﬁbroblasts (Fig. 3) (Peng et al.,
2013). Amongst them, subepithelial cells, wrapping cells, and
interstitial ﬁbroblasts are ﬁbroblast subtypes. Interestingly, sub-
epithelial cells, located between the epithelium and smooth
muscle, are in close proximity to the basal cells. During prostate
Fig. 2. Schematic diagrams illustrating prostate development and epithelial cell differentiation in mouse. (A) At E15, the UGS consists of a psuedostratiﬁed epithelium, and
all cells co-express p63 and CK8. (B) At E17, prostatic ducts start to form. In the proximal regions (X), epithelial cells separate into lineage restricted CK8þ cells lining the
lumen and likely bipotent p63þCK8þ cells at the base. In the distal regions that have not canalized (Y), epithelial cells co-express p63 and CK8. (C) At P1, prostatic ducts
elongate, branch, and arborize into networks. Epithelial cells consist of lineage restricted CK8þ luminal cells, p63þ basal cells, and Synþ neuroendocrine cells. Syn,
synaptophysin.
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development, a thin layer of mesenchymal cells termed lamina
propria located between the epithelium and smooth muscle has
been described (Abler et al., 2011). Consistent with our ﬁndings of
subepithelial cells in the adult mouse prostate, stromal cells
referred to as periductal ﬁbroblasts were observed using electron
microscopy in the adult rat prostate (Flickinger, 1972; Chang et al.,
1999). Future studies will be needed to determine whether
mesenchymal cells in the lamina propria during prostate devel-
opment give rise to subepithelial cells in the adult prostate.
The importance of stroma in prostate development and home-
ostasis has been well documented. In classic tissue recombination
experiments, androgen signaling was demonstrated to be required
in the stroma but is dispensable in the epithelium for the
induction of prostatic tissue (Cunha and Lung, 1978). In addition,
mosaic ablation of the TGFβ type II receptor in a subset of
ﬁbroblasts was found to result in epithelial neoplasia (Bhowmick
et al., 2004; Franco et al., 2011; Kiskowski et al., 2011). Moreover,
overexpression of FGF10 by UGM promotes cancer in adult
dissociated prostate epithelial cells grafted under the kidney
capsule (Memarzadeh et al., 2007). Reciprocal paracrine signalings
between the epithelium and the stroma are not only crucial for
prostate development but also continue to play key roles in
maintaining tissue homeostasis in the adult prostate.
Prostate regeneration and adult stem cells
The adult mouse prostate is a quiescent organ with sparse cell
proliferation being reported at the distal tips of ducts (Sugimura et
al., 1986c). The maintenance of adult prostate cells and architec-
ture requires androgen. Upon castration, about 35% of the ductal
tips and branch-points are lost in distal regions of the prostatic
ducts over a 2–3 week period (Sugimura et al., 1986b). The
involution process is more rapid and profound in the VP than in
the other lobes (Banerjee et al., 1995). Moreover, castration causes
apoptotic death of both epithelial and stromal cells (Banerjee et al.,
1995). In the epithelium, luminal cells are preferentially lost
compared to basal cells following castration (English et al., 1987).
Strikingly, 14 days after the administration of androgen to an
involuted prostate, the prostatic ducts completely regenerate
(Sugimura et al., 1986b).
Because cycles of involution and regeneration can be repeated
over 30 times (Isaacs, 1985), it is generally agreed that a popula-
tion of castration-resistant prostate stem cells exists that is
capable of long-term self-renewal. To identify epithelial stem cells
in the adult prostate by virtue of their slow cycling nature,
Tsujimura et al. (2002) castrated male mice at 3 weeks, gave BrdU
during the ﬁrst round of regeneration to label almost all the
epithelial cells, and then subjected the mice to up to 16 cycles of
involution and regeneration. They found that slow cycling cells,
detected by BrdU label-retention, are enriched in the proximal
region of prostatic ducts (Tsujimura et al., 2002); moreover,
epithelial cells isolated from the proximal region of ducts possess
higher in vitro proliferative potential and form more elaborate
branched glandular structures in collagen gels compared to
epithelial cells from the distal region (Tsujimura et al., 2002).
Importantly, label-retaining cells are distributed nearly equally in
both luminal and basal cells in the proximal region (Tsujimura et
al., 2002), providing the ﬁrst in vivo evidence that epithelial stem
cells may exist in both luminal and basal compartments. Based on
these ﬁndings, Tsujimura et al. (2002) proposed a model in which
epithelial stem cells are enriched in the proximal region of
prostatic ducts, in a stem cell niche surrounded by a thick bundle
of smooth muscle cells that express a high level of TGFβ (Nemeth
et al., 1997). During castration, TGFβ signaling decreases proxi-
mally and increases distally (Salm et al., 2005). The increased TGFβ
signaling in the distal region likely results in the apoptosis of cells
in this region (Salm et al., 2005). In the proximal regions, TGFβ
signaling decreases and WNT signaling increases (Placencio et al.,
2008), thus favoring cell survival. In addition to WNT signaling,
FGF signaling has been proposed to antagonize the effect of TGFβ
(Salm et al., 2005; Franco et al., 2011). Tsujimura et al. (2002)
further proposed that during regeneration, proximal epithelial
stem cells give rise to young transit-amplifying cells in distal
regions that repopulate the ducts. This model has had a major
inﬂuence on the interpretation of studies examining the nature of
epithelial stem cells and their niche; yet, it has not been rigorously
tested in situ. Recently, genetic mouse models have provided a
powerful approach to trace the fate of distinct cell types in situ (see
below); however, currently no tools are available to preferentially
label proximal versus distal cells in the prostate. When such tools
are available in the future, it will be possible to test whether a
proximal–distal hierarchy of cell lineage exists in the adult
prostate.
Multiple stem cell markers have been identiﬁed to distinguish
epithelial stem cells from the rest of the cells in the adult prostate
(Fig. 3). Stem cells in the proximal region of mouse prostatic ducts
can be puriﬁed by FACS (Fluorescence-Activated Cell Sorting) by
virtue of their high expression of SCA1 (Burger et al., 2005; Xin
et al., 2005). These SCA1high cells are enriched in proximal ducts and
also express CD49f (α6 integrin) and the anti-apoptotic factor BCL2,
which are characteristic markers for a variety of adult stem cells in
other organs (Burger et al., 2005). Further FACS studies using
different combinations of markers have identiﬁed two seemingly
distinct stem cell populations (based on in vitro assays and in vivo
transplant experiments): SCA1þCD49fþTROP2high (Goldstein et al.,
2008) and SCA1þCD133þCD44þCD117þ (Leong et al., 2008).
Fig. 3. Schematic diagrams of adult stem cells and their markers in mouse. (A) FACS studies have identiﬁed two seemingly distinct stem cell populations mainly among the
basal cells: Sca-1þCD49fþTrop2high and Sca-1þCD133þCD44þCD117þ . SMC, smooth muscle cell. (B) GIFM studies have identiﬁed CARNs (Castration Resistant Nkx3.1-
expressing cells) in the luminal cells of involuted prostates. Luminal cells and basal cells marked by K8-GIFM and K14-GIFM, respectively are self-sustained, whereas CARN
cells give rise to basal and luminal cells during regeneration. We propose that the four subtypes of stromal cells marked by Gli1-GIFM each have the ability for long-term self-
renewal. Smooth muscle cells marked by Sma-CreER have been shown to be self-sustained.
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Notably, these two epithelial stem cell populations mainly exist in
the basal cell compartment based on immunoﬂuorescence staining
of prostate sections with CD49f (Lawson et al., 2007) or CD117
(Leong et al., 2008). These stem cell markers provide useful tools to
stratify epithelial cells in terms of their potential stemness in
culture or in transplant experiments. However, it is less clear how
these markers relate to the machinery that empowers stemness to
these epithelial stem cells, especially in vivo. A study of the
Polycomb group transcriptional repressor Bmi-1 recently shed light
on this matter. Cells expressing Bmi-1 are enriched in the proximal
region of the prostate as well as in the SCA1þCD49fþ stem cells
(Lukacs et al., 2010). Using shRNA knockdown, Lukacs et al. (2010)
demonstrated that Bmi-1 plays an essential role in self-renewal of
epithelial stem cells, measured by in vitro serial sphere forming
assays and in vivo tissue recombination studies. Future studies are
needed to establish links between signaling pathways or down-
stream targets of Bmi-1 that regulate stemness. Of possible rele-
vance, signaling pathways such as Notch (Carvalho et al., 2014) and
WNT (Kharaishvili et al., 2011) have been implicated in the multi-
potency of epithelial stem cells and the lineage relationship
between luminal and basal cells. For example, Notch ligands are
expressed mainly by the basal cells and Notch signaling is active in
both the luminal and basal cells (Valdez et al., 2012). Ectopic Notch
activation in mouse prostate results in a decrease in basal cell
number and an increase in luminal cell number (Valdez et al., 2012),
suggesting Notch signaling plays an important role in maintaining
the balance between these two cell types.
Importantly, when basal cells are isolated from the human or
mouse prostate and transplanted under the mouse renal capsule
together with the mouse UGM, they give rise to both basal and
luminal cells (Lawson et al., 2007; Goldstein et al., 2010). However,
when luminal cells are isolated and similarly transplanted, they do
not give rise to basal cells (Goldstein et al., 2010). One interpreta-
tion of these experiments is that basal cells are bi-potent whereas
luminal cells are uni-potent. However, this interpretation is not
upheld by in situ lineage-tracing studies in mice, where both
luminal and basal cells are primarily lineage restricted (see below).
More recently, mouse genetic tools have provided a powerful
approach to mark cells and follow their fate in situ during
androgen-mediated regeneration following castration-induced
involution (Figs. 3 and 4). The homeobox transcription factor
Nkx3.1 is one of the earliest speciﬁc markers for the prostate
epithelium during ductal morphogenesis (Abate-Shen et al., 2008).
Using Genetic Inducible Fate Mapping (GIFM) (Joyner and Zervas,
2006) and Nkx3.1CreER; R26YFP mice, Wang et al. (2009) identiﬁed a
rare luminal epithelial population in the involuted prostate,
termed CARNs (Castration-resistant Nkx3.1-expressing cells), that
can repopulate both luminal and basal compartments during
regeneration, indicating their bipotential ability. Subsequently,
Choi et al. (2012) used K14-CreER and K8-CreER transgenes to fate
map basal and luminal cells, respectively in the adult prostate
during two rounds of involution and regeneration. Surprisingly,
they found that basal and luminal cells are independently self-
sustained, indicating that cells that are lost either are replaced by
unipotent stem/progenitor cells or simply by self-duplication (Choi
et al., 2012). A different study using K5-CreER to fate map basal
cells after more rounds of involution and regeneration found that a
rare population of basal cells can contribute to both luminal and
basal cells after 5 but not 3 rounds, indicating their bipotential
ability when forced to regenerate to a great extent (Wang et al.,
2013). It is still not clear the degree to which the cells marked in
these studies overlap, and thus whether the difference in the two
results is due to the different Cre driver lines used. It is important
to note the number of cycles of involution and regeneration used
in each experiment, as more cycles might force stem cells to
regenerate to a greater extent and thus reveal bipotentiality.
Nevertheless, these studies suggest that epithelial basal and
luminal stem cells in the adult prostate are much more lineage-
restricted when assayed in situ by genetic inducible fate mapping
during involution and regeneration compared to tissue recombi-
nation studies in which UGM and isolated basal cells are mixed to
induce cell expansion and differentiation in culture or after
transplant.
Compared to epithelial stem cells, much less is known about
stromal stem cells in the prostate. Since during castration both
epithelial cells and stromal cells die (Banerjee et al., 1995; Peng
et al., 2013), both cell types need to be replenished. The existence
of stromal stem cells was suggested by in vitro culture of primary
stromal cells from BPH tissues (Lin et al., 2007). Such stromal cells
can differentiate into smooth muscle cells, osteocytes, and adipo-
cytes under speciﬁc culture conditions (Lin et al., 2007). Our in vivo
GIFM studies uncovered that all four prostate stromal subtypes are
replenished by stem cells for over 12 rounds of involution and
regeneration (Peng et al., 2013). To test whether multipotent or
unipotent stromal stem cells exist, a Sma-CreER transgene was
used to fate map smooth muscle cells over 6 rounds of involution
and regeneration. The study revealed that smooth muscle cells are
replenished primarily by preexisting smooth muscle actin (Sma)-
expressing cells (Peng et al., 2013). By extrapolation, four stromal
subtypes are likely replenished by their own stem cells, a hypoth-
esis that parallels the epithelial side where each epithelial subtype
is replenished mainly by distinct epithelial stem cells when
assayed by GIFM.
Hedgehog signaling: an overview
The most common mode of action by HH signaling is through a
paracrine mode in which HH producing cells are situated close to,
but are a different cell type from, those receiving HH signaling. In
mammals, three homologs of the Drosophila hedgehog (HH)
protein family exist: sonic hedgehog (SHH), Indian hedgehog
(IHH) and desert hedgehog (DHH). In HH producing cells, HH
ligands undergo extensive post-translational modiﬁcation. SHH,
the most studied mammalian HH ligand, undergoes autoproteo-
lytic cleavage (Perler, 1998) to generate an amino-terminal peptide
that is linked to cholesterol and palmitatic acid (Pepinsky et al.,
1998; Taylor et al., 2001). The distance HH travels to exert its
function differs between tissues but can be up to 300 μm in the
limb bud of vertebrates (Briscoe and Therond, 2013). In HH
receiving cells, HH signals through the core receptor Patched 1
(PTCH1), a 12-pass transmembrane protein (Marigo et al., 1996;
Stone et al., 1996) and three co-receptors: CDO, BOC, and GAS1
(Okada et al., 2006; Tenzen et al., 2006; Allen et al., 2007).
Mammals have a second Ptch gene, Ptch2, with an expression
pattern that does not fully overlap with Ptch1 expression
(Motoyama et al., 1998a, 1998c). Without HH ligand, PTCH1
represses the activity of smoothened (SMO), a seven-pass G-pro-
tein-coupled membrane protein, through an unknown mechan-
ism. The binding of a HH ligand to PTCH1 removes the inhibition
of SMO and thus turns on the signaling pathway.
SMO activation leads to a change in the balance of the repressor
and activator forms of the GLI zinc-ﬁnger transcription factors. Three
Gli genes are present in mammals, Gli1, Gli2, and Gli3, each with
both speciﬁc and redundant functions in the nervous system
(Motoyama et al., 1998b; Park et al., 2000; Bai and Joyner, 2001;
Bai et al., 2002, 2004; Persson et al., 2002; Motoyama et al., 2003;
Petrova et al., 2013). When the pathway is in the “off” state (SMO is
inactive), GLI2/GLI3 are phosphorylated and proteolytically pro-
cessed, leading to the conversion of GLI3, and to a lesser extent
GLI2 into transcriptional repressors (Wang et al., 2000; Bhatia et al.,
2006; Pan et al., 2006; Wang and Li, 2006). When the pathway is in
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the “on” state, SMO activation inhibits GLI2/GLI3 proteolysis and
promotes the formation of GLI2, and to a lesser extent GLI3
activators. GLI2/GLI3 activators turn on expression of target genes,
including Gli1 (Sasaki et al., 1999; Bai et al., 2004; Smelkinson et al.,
2007). GLI1 functions as a constitutive activator that exerts positive
feedback on the HH signaling pathway, but it is dispensable for
normal development, including the prostate (Park et al., 2000; Bai et
al., 2002; Doles et al., 2006).
Vertebrate HH signaling requires the primary cilium, a slim
microtubule-based organelle that projects from the surface of most
vertebrate cells (Goetz and Anderson, 2010). Mouse genetics studies
demonstrated that mutations affecting intraﬂageller trafﬁcking dis-
rupt HH signal transduction and result in HH loss and gain-of-
function phenotypes (Huangfu et al., 2003), providing the ﬁrst
evidence that cilia play an essential role for processing GLI proteins
into activators and repressors. PTCH1 is enriched in primary cilia in
the absence of HH and moves out of cilia in the presence of HH
(Rohatgi et al., 2007). In response to HH, SMO is enriched along the
primary cilium and activates the pathway by antagonizing the activity
of suppressor of fused (SUFU), an important negative regulator of
mammalian HH signaling (Cooper et al., 2005; Svard et al., 2006).
Removal of SUFU inhibition allows GLI2/GLI3 to become activators
and translocate into the nucleus, where they promote expression of
HH target genes.
Hedgehog signaling in prostate development and homeostasis
During ductal morphogenesis, Shh is expressed in the epithe-
lium of nascent UGS buds and in the growing tips of the elongating
prostate ducts (Podlasek et al., 1999). The pattern of Shh expres-
sion is mirrored by the expression of Gli1 and Ptch1 in the adjacent
UGS mesenchyme (Lamm et al., 2002; Pu et al., 2004). HH
signaling was ﬁrst thought to be absolutely required for inducing
prostate budding based on studies of neutralizing antibody treat-
ment of E15 UGS grafts implanted under the renal capsule and
pharmacological inhibition of HH signaling in prostate organ
cultures (Podlasek et al., 1999; Lamm et al., 2002). Consistent with
this idea, Shh / embryos at E18.5 show a complete absence of
prostatic ductal budding (Berman et al., 2004). However, subse-
quent studies showed that apparently normal glandular structures
can be derived from Shh null mutant mice when the UGS is
implanted under the renal capsule of adult male mice (Berman
et al., 2004) or cultured in the presence of androgen (Freestone
et al., 2003; Berman et al., 2004), suggesting the defect in Shh null
mutants is due to insufﬁcient levels of androgens. Ihh expression
was up-regulated in both grafted and cultured Shh null mutant
UGS and might therefore compensate for the loss of Shh (Doles
et al., 2006). Gli2 null mutant mice exhibit reduced ductal morph-
ogenesis and perturbed epithelial differentiation (Doles et al.,
2006), which cannot be rescued by exogenous androgen supple-
mentation, indicating that the phenotypes are not due to hypo-
gonadism as seen in Shh null mutants (Doles et al., 2006). Thus, it
is likely that HH (possibly IHH and SHH) signals through GLI2 to
regulate prostate duct development.
The effects of HH signaling activation on ductal morphogenesis
appear to be stage dependent. Using cultured UGS from P2 rats,
Wang et al. (2003) showed that unlike with embryonic UGS,
inhibition of HH signaling by cyclopamine results in enlarged
ductal tips and increased ductal branching, whereas addition of
SHH recombinant protein increases the number of differentiated
epithelial cells (Wang et al., 2003). To resolve the different results
observed with different stages of prostate tissue in culture in
different studies, Yu and Bushman (2013) studied the effect of
ectopic HH pathway activation on prostate ductal growth using
in vitro organ cultures and in vivo transgenic mouse models. They
found that co-culture of prostate epithelium with a mesenchymal
cell line overexpressing SMO-M2 (an active form of SMO) results
in increased ductal growth when embryonic prostate tissue is used
but decreased ductal growth when postnatal tissue is used (Yu and
Bushman, 2013). Moreover, they found that activation of HH
signaling in the mesenchyme of mice using Fsp-Cre; R26LSL-SmoM2
mice that conditionally express SMO-M2 in the mesenchyme from
mid-gestation onwards results in an increase in epithelial prolif-
eration in embryos, but inhibition of epithelial proliferation post-
natally (Yu and Bushman, 2013). The stage-dependent effects of
paracrine HH signaling are likely due to differences in the
response of the stroma to HH signaling at different developmental
stages, for example in regulation of secretion of inhibitors of
epithelial growth such as Activin A and TGFβ1 (Wang et al.,
2003). Of particular interest, this plausible stage-dependent stro-
mal response might be tightly linked to the different cell types and
composition at different developmental stages. For example,
undifferentiated mesenchyme might respond differently to active
HH signaling compared to mature smooth muscle cells.
Fig. 4. Schematic diagrams of hedgehog signaling pathway in vertebrate. (A) In the absence of HH, PTCH1 prevents SMO from translocating to the cilia. GLI2/3 are associated
with SUFU, which promotes GLI2/3 phosphorylation. GLI2/3 are proteolytically processed, which leads to the conversion of GLI3, and to a lesser extent GLI2 into
transcriptional repressors. (B) In the presence of HH, SMO translocates to the cilia, which promotes the dissociation of the SUFU–GLI2/3 complex. The proteolysis of GLI2/3 is
inhibited, which promotes the formation of GLI2, and to a lesser extent GLI3 activators.
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In the adult prostate, our recent study using knock-in reporter
mice for several key components of the HH pathway has revealed
that Shh is expressed speciﬁcally from the basal epithelial cells and
signals to the surrounding stromal cells (Peng et al., 2013). In most
regions of the adult mouse prostate, except the most proximal
part, basal cells express Shh whereas luminal cells do not (Peng
et al., 2013). Furthermore, a subset of the four stromal subtypes
expresses Gli1, indicating cells experiencing a high-level of HH
signaling, whereas most stromal cells express Gli2 indicating that
they are capable of responding to HH signaling (Peng et al., 2013).
Interestingly, the basal cells in addition to many stromal cells
express Gli3, encoding the major repressor of the pathway (Peng
et al., 2013). Considering that during involution luminal cells
preferentially die compared to basal cells (English et al., 1987), it
is tempting to propose that Gli3 plays a role in conferring cast-
ration resistance to the basal cells. The functional role of GLI3 in
the basal cells requires further study. Nevertheless, it is clear that
in the adult prostate, HH signals primarily from the epithelium to
the stroma. Thus, the paracrine mode of action is preserved from
the developing prostate to the adult prostate.
Hedgehog signaling in human cancers
Hedgehog signaling is aberrantly activated in a wide variety of
human cancers. Its mode of action can be categorized into four
classes. The ﬁrst class involves cell autonomous HH signaling and
results from activating mutations in HH pathway components that
render tumor cells independent of HH ligands. A classic example is
Gorlin syndrome, a dominant disorder characterized by hetero-
zygous loss-of-function mutations in PTCH1 (Gorlin, 2004).
Patients with Gorlin syndrome develop medulloblastoma, rhabdo-
sarcoma and basal cell carcinoma (Gorlin, 2004). The second class
of tumors involves an autocrine or juxtacrine mode of action such
that tumor cells secrete and respond to HH ligands. The third class
involves a paracrine mode of action in which tumor cells secrete
HH ligands and signal to the surrounding stroma, which in turn
secretes reciprocal paracrine signals that regulate tumor growth.
In the fourth class, a reverse paracrine mode of action is active in
which stromal cells secrete HH ligands and tumor cells respond.
Hedgehog signaling in prostate cancer is thought to mainly
function by the third mode (see below).
Prostate cancer
Prostate cancer is the second leading cause of cancer death in
men in the United States (Siegel et al., 2013) and the second most
common cause of cancer among men worldwide (Ferlay et al.,
2010). Current treatments of localized prostate cancer include
surgery and radiation therapy. Patients with low-risk disease can
be managed with active surveillance. In cases of advanced cancer,
treatments primarily include androgen deprivation therapy, which
initially decreases the tumor size but castration-resistant cancer
eventually evolves and becomes refractory to any current treat-
ments (Wozney and Antonarakis, 2014). Tremendous effort has
been put into understanding how prostate cancer initiates and
progresses but many factors remain unclear. Relatively recently,
signaling pathways that play important roles during prostate
development, such as HH signaling, have drawn signiﬁcant atten-
tion due to the idea that cancer cells may awaken and harness
these pathways to promote their growth. Therefore, a thorough
understanding of how these pathways act in prostate cancer could
likely facilitate the development of more effective treatments.
Prostate adenocarcinoma can derive from both luminal and
basal cells. In 495% untreated prostate cancers, tumor cells
predominantly express luminal markers, whereas basal-like cells
are rare (Shen and Abate-Shen, 2010). Conditional deletion of Pten
in either luminal or basal cells in adult mice using K14-CreER or
K8-CreER, respectively, results in prostate cancer (Choi et al., 2012).
However, luminal cells are more susceptible to direct transforma-
tion, whereas basal cells appear to need to differentiate into
luminal cells before they undergo oncogenic transformation
(Choi et al., 2012). By contrast, tissue recombination studies have
shown that human basal cells can be more susceptible to malig-
nant transformation, at least in an ectopic graft assay. Overexpres-
sion of ERG, AKT, and AR in human prostate basal cells (isolated
based on CD49fhigh and TROP2high expression) generates prostate
cancer when the cells are combined with UGM and transplanted
subcutaneously into immunocompromised mice, whereas the
same manipulation of luminal cells (CD49low; TROP2high) fails to
generate prostate cancer (Goldstein et al., 2010). Therefore, lumi-
nal and basal cells are capable of initiation of prostate cancer but
the characteristics of tumor progression likely depend on the
cellular and genetic context. Of note, since in the aforementioned
studies malignant transformation was induced in luminal and
basal epithelial cells from different species (mouse and human),
one cannot exclude the possibility that there is an intrinsic
difference in the susceptibility of basal or luminal cells to malig-
nant transformation between species.
Numerous studies have indicated the importance of reciprocal
interactions between prostate stromal cells and tumor cells during
prostate cancer formation (Barron and Rowley, 2012). For example,
normal prostate epithelial cells give rise to intraepithelial neopla-
sia when combined with cancer-associated ﬁbroblasts (CAFs) but
not with normal ﬁbroblasts (Olumi et al., 1999). In human prostate
cancer, cancer-associated stroma is mainly composed of CAFs and
myoﬁbroblasts intermixed with a greatly reduced number of ma-
ture smooth muscle cells, compared to normal prostate stroma
which is predominantly composed of smooth muscle (Tuxhorn
et al., 2002). Myoﬁbroblasts express vimentin and a decreased
level of smooth muscle actin and are devoid of mature smooth
muscle markers such as calponin and desmin (Tuxhorn et al.,
2002). Signiﬁcantly, the volume of cancer-associated stroma in the
tumor is a predictor of disease-free survival (Ayala et al., 2003,
2011). The cell of origin for cancer-associated stroma is not clear.
Many cell types have been proposed to be the source including
ﬁbroblasts, smooth muscle cells, pericytes, and mesenchymal stem
cells (Barron and Rowley, 2012). However, none of the proposed
sources have been rigorously tested by using in vivo fate mapping
experiments.
Hedgehog signaling in prostate cancer
Aberrant activation of HH signaling has been implicated in
human prostate carcinogenesis. However, it is not clear whether
tumor cells secrete and respond to HH ligands in an autocrine
fashion (class 2) or tumor cells secrete HH ligands and stromal
cells respond (class 3). Studies from several groups have supported
the idea that paracrine HH signaling plays an important role in
prostate cancer progression. Similar to the normal adult prostate,
Fan et al. (2004) Shh expression was detected by in situ hybridiza-
tion in the tumor epithelium and Gli1 expression in the stroma. In
addition, genetically engineered Shh overexpression in the LNCaP
human cancer cell line was found to lead to increased stromal Gli1
expression and to accelerate tumor growth in a xenograft tumor
model (Fan et al., 2004), supporting a paracrine mode of HH
action. Furthermore, Ibuki et al. (2013) showed that the growth of
LNCaP cells was signiﬁcantly delayed in castrated mice treated
with TAK-441, a smoothened antagonist, indicating an important
role of HH signaling in the development of castration resistance. In
the TAK-441-treated xenografts, expression of murine Gli1 was
suppressed, while expression of human GLI1 in tumor cells was
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unaffected (Ibuki et al., 2013). Since the LNCaP cancer cells were
implanted under the skin, it is possible that the dermal stromal
cells respond to Shh the same way as the normal prostate stromal
cells and that reciprocal paracrine signaling augments tumor
progression.
On the other hand, autocrine HH signaling in cancer epithelial
cells has been reported (Karhadkar et al., 2004; Sanchez et al.,
2004; Tzelepi et al., 2011). Aberrant activation of HH signaling,
measured by GLI1 and PTCH1 expression in whole tumor tissue
using quantitative RT-PCR (qRT-PCR), was found to be more
prevalent in metastatic prostate cancer than in localized prostate
cancer (Karhadkar et al., 2004). However, since epithelial and
stromal cells were not separated in this study, it is equally possible
that increased stromal GLI1 expression accounts for the overall
increase in GLI1 levels. Tzelepi et al. (2011) detected higher PTCH1
expression in the epithelium of metastatic tissue compared to
primary cancer tissue using immunohistochemistry. If the anti-
body is reliable, the result indicates that a shift from a paracrine to
autocrine mode of action can occur during cancer progression. The
seemingly different results regarding whether HH functions in a
paracrine or an autocrine manner, or both, likely reﬂect the
difﬁculties of detecting components of the HH pathway in human
prostate cancer. Moreover, not only is there a lack of reliable
antibodies to components of the HH pathway, but the hetero-
geneity of prostate cancer within one patient and between
patients, and the difﬁculty of cleanly separating the epithelium
from the stroma also present major challenges. In this regard,
genetic mouse models provide a valuable tool to address the mode
of action of HH signaling in vivo and its role during prostate cancer
formation.
In the SV40 T-antigen based LADY prostate tumor model, Shh
expression was found to be decreased, whereas the expression of
Gli1 was not altered as measured by qRT-PCR of whole tumor
tissue (Gipp et al., 2007). Interestingly, Ihh expression is increased
in LADY tumors compared to the normal prostate (Gipp et al.,
2007). The maintenance of a normal Gli1 level could actually
indicate an increase in stromal Gli1 expression, given that the
proportion of stromal cells is usually decreased compared to
epithelial cells in prostate tumors. The increased stromal Gli1
expression could then be due to an increase in Ihh expression. It is
unclear whether aberrant activation of the HH pathway in the
stroma is sufﬁcient to generate or accelerate progression of
prostate cancer. Interestingly, overexpression of SHH ligand by
electroporation of the adult mouse prostate is sufﬁcient to cause
prostate cancer in 90 days (Chang et al., 2011). In contrast,
conditional expression of SMO-M2, a constitutively active form
of SMO, in the postnatal prostate epithelium using a Probasin-Cre
transgene does not increase epithelial proliferation or result in
cancer (Mao et al., 2006). Since overexpression of SHH ligand can
have effects on both the epithelium and the stroma, it is possible
that activation of the HH pathway in both compartments is
required to initiate prostate cancer, or that aberrant activation of
the pathway in the stroma alone is sufﬁcient to generate prostate
cancer. Given that Gli3 is expressed in basal cells of the epithelium
(Peng et al., 2013), this epithelial cell type has at least some of the
machinery necessary for HH signaling.
An important question is whether there is crosstalk between
HH signaling and androgen receptor (AR) signaling in prostate
cancer. As castration-resistant prostate cancer (CRPC) continues to
be dependent on AR signaling which is active despite low serum
levels of androgen (Chen et al., 2008), one possible mechanism of
castration resistance is through activation of other signaling path-
ways both inside the tumor cells and in the tumor microenviron-
ment. Therefore, inhibition of signaling pathways that assist the
activation of AR signaling likely represent a compelling combined
therapeutic approach for prostate cancer. There is in vitro evidence
for an interaction between HH and AR signaling. When culture
conditions were switched from an androgen-supplemented to an
androgen-depleted medium SHH expression was increased in the
LNCaP human prostate cancer cell line (Azoulay et al., 2008; Chen
et al., 2009). Providing functional evidence for SHH production,
conditioned medium from the androgen-deprived LNCaP cells
increased Gli1 expression in cultured mouse ﬁbroblasts (Chen et
al., 2009), indicating that androgen-deprived LNCaP cells can
induce paracrine HH signaling in the stromal cells. Moreover,
treatment of primary human prostate stromal cells with SAG, a
HH agonist, or with a lentivirus that expresses a constitutively
active GLI2 leads to increased androgen production from the
conversion of androgen precursors supplemented in the culture
medium (Levina et al., 2012), indicating that paracrine HH signal-
ing in stromal cells could play a role in the local production of
androgen. Furthermore, combined treatment of mice with an AR
inhibitor and a HH inhibitor was found to suppress CRPC growth in
a xenograft mouse model of prostate cancer more effectively than
treatment with either agent alone (Gowda et al., 2013). Future
clinical trials of HH inhibitors with AR inhibitors will be needed to
test the efﬁcacy of this combination therapy on patients
with CRPC.
Since HH signaling is active in both normal stroma and cancer-
associated stroma, an important question is how stromal cells in
these two different states are intrinsically different and lead to
overtly different effects on the epithelium: in the normal prostate,
a homeostatic balance exists between the epithelium and stroma,
whereas during cancer formation the balance is disrupted such
that the nature of the stroma is changed and unchecked expansion
of luminal cells is favored. Considering the effects of HH activation
on ductal morphogenesis are stage-dependent during prostate
development, it is possible that cancer-associated stromal cells
recapitulate properties of prenatal mesenchyme, where expansion
of the cells is stimulated by SHH. Indeed, transcriptional studies
identiﬁed common genes that are regulated by SHH in the
mesenchyme of the developing prostate and in the stroma of
SHH-overexpressing xenograft tumors (Shaw et al., 2009) and in
primary CAFs from human prostate tumors (Wilkinson et al.,
2013). However, it is equally possible that cancer-associated
stromal cells resemble postnatal stroma and thus inhibiting HH
signaling could potentially worsen the disease. Indeed, recent
studies of pancreatic cancer provided compelling evidence that
HH signaling reduces tumor progression (Lee et al., 2014; Rhim
et al., 2014). To distinguish between the two possible functions of
HH, it will be necessary to decipher how the network involving HH
signaling is wired in the cancerous context compared to the
normal prostate. In this regard, it also is important to identify
the HH target genes that are differentially expressed in the normal
prostate and cancer, and likely in different subtypes of prostate
cancer.
Conclusion
Recent experiments using GIFM have uncovered that prostatic
epithelial cells become lineage-restricted (from multipotent to
unipotent) during postnatal development. In the adult, both
epithelial and stromal stem cells are largely unipotent when
assayed in vivo during a limited number of rounds of regeneration.
SHH signals primarily in a paracrine mode from the epithelium to
the stroma both during prostate development and in the adult. In
prostate cancer, HH likely also signals mainly through a paracrine
mode. Stromal cells in the cancerous tissue are phenotypically
different from their normal counterparts, and thus the molecular
and cellular consequences of HH signaling are likely to differ
during development in comparison to adult homeostasis, and
Y.-C. Peng, A.L. Joyner / Developmental Biology 400 (2015) 94–104 101
could depend on the particular prostate tumor. Understanding the
difference between normal stroma and cancer-associated stroma,
and identifying the HH target genes differentially expressed
between the different contexts will be key to understanding the
stage and tumor-speciﬁc roles of HH signaling and for devising
innovative therapies to combat prostate cancer.
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